licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2011.04.29; Accepted: 2011.06.03; Published: 2011.06.08 Adoptive cell therapy can be an effective treatment for some patients with advanced cancer. This report summarizes clinical trial results from the Surgery Branch, NCI, investigating tumor infiltrating lymphocytes (TIL) and gene engineered peripheral blood T cells for the therapy of patients with melanoma and other solid tumors. Key words: TIL, melanoma, NY-ESO-1, interleukin-2, lymphodepletion Adoptive T cell therapy (ACT) consists of isolating tumor reactive lymphocytes from a patient, growing and activating them in the laboratory, and infusing them back into the autologous patient . ACT can be an effective treatment for patients with refractory melanoma, and potentially other advanced cancers. Clinical trials in the Surgery Branch of th
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.